-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585

Benzinga·07/13/2026 18:18:03
語音播報
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $545 to $585.